Document Type : Review Article
Author
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Abstract
Epilepsy affects approximately 50 million individuals globally, with nearly 30% exhibiting refractory symptoms despite advances in antiseizure medications. Consequently, there is an urgent need for adjunctive therapies targeting underlying pathophysiological mechanisms such as oxidative stress and neuronal hyperexcitability. This review comprehensively evaluates the therapeutic potential of melatonin in epilepsy management, synthesizing evidence from preclinical models, clinical trials, and mechanistic studies published in contemporary literature.
Melatonin demonstrates pleiotropic anticonvulsant properties mediated through MT1/MT2 receptor-dependent and independent pathways. Key mechanisms include potent antioxidant activity via ROS scavenging, glutathione homeostasis, and Nrf2 pathway activation. Additionally, it exerts anti-inflammatory effects through NF-κB suppression and microglial polarization, while restoring excitatory-inhibitory balance by enhancing GABAergic transmission and inhibiting glutamatergic excitotoxicity. Specific molecular targets include CREB phosphorylation, BDNF expression, and ROR-mediated circadian gene regulation. Furthermore, melatonin preserves mitochondrial integrity and synchronizes circadian rhythms, often disrupted in epileptogenesis.
Preclinical investigations consistently report reduced seizure severity and frequency across various animal models, including PTZ and kainic acid-induced epilepsy. Human clinical trials, although heterogeneous, indicate that adjunctive melatonin significantly ameliorates seizure severity and sleep disturbances in adult populations, with a favorable safety profile. However, effects on seizure frequency remain inconsistent, particularly in pediatric cohorts with infantile spasms. Meta-analytic data support improvements in severity and sleep latency without increased adverse events.
In conclusion, melatonin represents a promising, safe, and accessible adjunctive therapy for epilepsy, particularly for mitigating seizure severity and comorbid sleep disorders. Future research should prioritize large-scale, multicenter randomized controlled trials to establish standardized dosing protocols and identify patient subgroups most likely to benefit. Addressing discrepancies in administration timing and long-term outcomes is essential to optimizing translational strategies and revolutionizing management for refractory epilepsy.
Keywords
Subjects